Literature DB >> 30001234

Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns.

Carlie S Sigel1, Esther Drill2, Yi Zhou3, Olca Basturk1, Gokce Askan1, Linda M Pak4, Efsevia Vakiani1, Tao Wang1, Thomas Boerner5, Richard K G Do6, Amber L Simpson5, William Jarnagin5, David S Klimstra1.   

Abstract

Intrahepatic cholangiocarcinomas are histologically heterogenous. Using a cohort of 184 clinically defined, resected intrahepatic cholangiocarcinomas, we retrospectively classified the histology into 4 subtypes: large duct (LD), small duct (SD) (predominantly tubular [SD1] or predominantly anastomosing/cholangiolar, [SD2]), or indeterminate. Then, we tested the 4 subtypes for associations with risk factors, patient outcomes, histology, and immunophenotypic characteristics. SD was the most common (84%; 24% SD1 and 60% SD2) with lower proportions of LD (8%), and indeterminate (8%). Primary sclerosing cholangitis was rare (2%), but correlated with LD (P=0.005). Chronic hepatitis, frequent alcohol use, smoking, and steatosis had no histologic association. LD was associated with mucin production (P<0.001), perineural invasion (P=0.002), CA19-9 staining (P<0.001), CK7, CK19, CD56 immunophenotype (P=0.005), and negative albumin RNA in situ hybridization (P<0.001). SD was histologically nodular (P=0.019), sclerotic (P<0.001), hepatoid (P=0.042), and infiltrative at the interface with hepatocytes (P<0.001). Albumin was positive in 71% of SD and 18% of LD (P=0.0021). Most albumin positive tumors (85%) lacked extracellular mucin (P<0.001). S100P expression did not associate with subtype (P>0.05). There was no difference in disease-specific or recurrence-free survival among the subtypes. Periductal infiltration and American Joint Committee on Cancer eighth edition pT stage predicted survival by multivariable analysis accounting for gross configuration, pT stage, and histologic type. pT2 had worse outcome relative to other pT stages. Significant differences in histology and albumin expression distinguish LD from SD, but there is insufficient evidence to support further subclassification of SD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30001234      PMCID: PMC6657522          DOI: 10.1097/PAS.0000000000001118

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

1.  Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.

Authors:  Mina Komuta; Olivier Govaere; Vincent Vandecaveye; Jun Akiba; Werner Van Steenbergen; Chris Verslype; Wim Laleman; Jacques Pirenne; Raymond Aerts; Hirohisa Yano; Frederik Nevens; Baki Topal; Tania Roskams
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  New staging system and a registry for perihilar cholangiocarcinoma.

Authors:  Michelle L Deoliveira; Richard D Schulick; Yuji Nimura; Charles Rosen; Gregory Gores; Peter Neuhaus; Pierre-Alain Clavien
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

3.  C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.

Authors:  Yi-Chen Yeh; Hao-Jan Lei; Ming-Huang Chen; Hsiang-Ling Ho; Ling-Ya Chiu; Chung-Pin Li; Yu-Chao Wang
Journal:  Am J Surg Pathol       Date:  2017-12       Impact factor: 6.394

4.  Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.

Authors:  Mohammad Shahid; Aysha Mubeen; Julie Tse; Sanjay Kakar; Adrian C Bateman; Darrell Borger; Miguel N Rivera; David T Ting; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

5.  The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Authors:  Cristina R Ferrone; David T Ting; Mohammed Shahid; Ioannis T Konstantinidis; Francesco Sabbatino; Lipika Goyal; Travis Rice-Stitt; Ayesha Mubeen; Kshitij Arora; Nabeel Bardeesey; John Miura; T Clark Gamblin; Andrew X Zhu; Darrell Borger; Keith D Lillemoe; Miguel N Rivera; Vikram Deshpande
Journal:  Ann Surg Oncol       Date:  2014-12-18       Impact factor: 5.344

6.  Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.

Authors:  Cédric Coulouarn; Catherine Cavard; Laura Rubbia-Brandt; Anne Audebourg; Florent Dumont; Sébastien Jacques; Pierre-Alexandre Just; Bruno Clément; Hélène Gilgenkrantz; Christine Perret; Benoît Terris
Journal:  Carcinogenesis       Date:  2012-06-13       Impact factor: 4.944

7.  Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models.

Authors:  Alexandre Doussot; Mithat Gonen; Jimme K Wiggers; Bas Groot-Koerkamp; Ronald P DeMatteo; David Fuks; Peter J Allen; Olivier Farges; T Peter Kingham; Jean Marc Regimbeau; Michael I D'Angelica; Daniel Azoulay; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2016-06-11       Impact factor: 6.113

8.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States.

Authors:  Sean F Altekruse; Jessica L Petrick; Alicia I Rolin; James E Cuccinelli; Zhaohui Zou; Zaria Tatalovich; Katherine A McGlynn
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

10.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.

Authors:  Shahid A Khan; Brian R Davidson; Robert D Goldin; Nigel Heaton; John Karani; Stephen P Pereira; William M C Rosenberg; Paul Tait; Simon D Taylor-Robinson; Andrew V Thillainayagam; Howard C Thomas; Harpreet Wasan
Journal:  Gut       Date:  2012-08-15       Impact factor: 23.059

View more
  11 in total

1.  Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.

Authors:  Tao Wang; Esther Drill; Efsevia Vakiani; Linda Ma Pak; Thomas Boerner; Gokce Askan; Juan Manuel Schvartzman; Amber L Simpson; William R Jarnagin; Carlie S Sigel
Journal:  Hum Pathol       Date:  2019-05-21       Impact factor: 3.466

2.  Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.

Authors:  Sungeun Park; Youngeun Lee; Haeryoung Kim; Mi Hye Yu; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2022-03-30       Impact factor: 12.430

3.  Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma.

Authors:  Yeon Seung Chung; Youngsic Jeon; Jeong Eun Yoo; Taek Chung; Hyang Joo Ryu; Hyunki Kim; Hyungjin Rhee; Young Nyun Park
Journal:  Hepatol Int       Date:  2022-10-17       Impact factor: 9.029

4.  Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.

Authors:  Kwun Wah Wen; Peter S Rabinovitch; Dongliang Wang; Aras N Mattis; Linda D Ferrell; Won-Tak Choi
Journal:  Virchows Arch       Date:  2020-04-15       Impact factor: 4.064

Review 5.  Early detection of intrahepatic cholangiocarcinoma.

Authors:  Mami Hamaoka; Kazuto Kozaka; Osamu Matsui; Takahiro Komori; Takashi Matsubara; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Wataru Koda; Toshifumi Gabata; Satoshi Kobayashi
Journal:  Jpn J Radiol       Date:  2019-08-01       Impact factor: 2.374

Review 6.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 7.  Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.

Authors:  Taek Chung; Young Nyun Park
Journal:  Front Med (Lausanne)       Date:  2022-03-31

8.  Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.

Authors:  Sylvie Job; Delphine Rapoud; Alexandre Dos Santos; Patrick Gonzalez; Christophe Desterke; Gérard Pascal; Nabila Elarouci; Mira Ayadi; René Adam; Daniel Azoulay; Denis Castaing; Eric Vibert; Daniel Cherqui; Didier Samuel; Antonio Sa Cuhna; Agnès Marchio; Pascal Pineau; Catherine Guettier; Aurélien de Reyniès; Jamila Faivre
Journal:  Hepatology       Date:  2020-08-16       Impact factor: 17.425

9.  Association between Immunohistochemistry Markers and Tumor Features and Their Diagnostic and Prognostic Values in Intrahepatic Cholangiocarcinoma.

Authors:  Jiannan He; Cao Zhang; Qinye Shi; Fangping Bao; Xiang Pan; Yue Kuai; Jingjin Wu; Li Li; Ping Chen; Yian Huang; Jianhong Xu
Journal:  Comput Math Methods Med       Date:  2022-04-28       Impact factor: 2.809

Review 10.  Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review.

Authors:  Mukul Vij; Yogesh Puri; Ashwin Rammohan; Gowripriya G; Rajesh Rajalingam; Ilankumaran Kaliamoorthy; Mohamed Rela
Journal:  World J Gastrointest Oncol       Date:  2022-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.